MetaCap

Atara Biotherapeutics (ATRA) vs Neumora Therapeutics (NMRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Atara Biotherapeutics (ATRA) has outperformed Neumora Therapeutics (NMRA) over the past year, losing 53.7% versus a loss of 85.7%. Atara Biotherapeutics is the larger company by market cap ($64.5 million vs $63.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATRA-53.73%NMRA-85.67%
+61%-16%-93%
Nov 21, 20251 yearNov 20, 2026
ATRA-83.45%NMRA-97.95%
+28%-38%-104%
Sep 11, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATRA versus NMRA key metrics
MetricATRANMRA
Share price$6.33$0.3339
Market cap$64.49M$63.01M
1-day change-0.16%-3.78%
YTD return-65.01%-81.35%
1-year return-53.73%-85.67%
5-year return-98.56%—
Forward P/E3.96—
EPS (TTM)$-1.12$-1.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$120.77M—
Revenue growth (YoY)-6.33%—
Net income (latest FY)$32.69M$-236.93M
Operating margin29.69%—
Net margin27.07%—
52-week high$19.15$3.65
52-week low$3.92$0.301
Distance from 52-week high-66.94%-90.85%
Analyst consensusbuybuy
Avg. price target upside+115.96%+1696.95%
Average volume35.46K1.69M
Shares outstanding10.19M188.69M
Employees1063
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ATRA has outperformed NMRA by 31.9 percentage points over the past year.

About Atara Biotherapeutics

ATRA stock →

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees

About Neumora Therapeutics

NMRA stock →

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees

ATRA vs NMRA FAQ

Which is bigger, Atara Biotherapeutics or Neumora Therapeutics?

Atara Biotherapeutics (ATRA) is larger, with a market capitalization of $64.49M compared with $63.01M for Neumora Therapeutics (NMRA).

Which stock has performed better over the past year, ATRA or NMRA?

ATRA returned -53.73% over the past 12 months, compared with -85.67% for NMRA (price return, excluding dividends). Past performance does not predict future results.

Are Atara Biotherapeutics and Neumora Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons